Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1034 | 1034 | 1082 | 1252 | 1304 | 1746 |
Fund Return | 3.41% | 3.41% | 8.21% | 7.78% | 5.45% | 5.73% |
Place in category | 344 | 344 | 264 | 207 | 159 | 93 |
% in Category | 53 | 53 | 39 | 44 | 36 | 29 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
HSBC American Index Fund Accumulati | 13.67B | 11.23 | 14.50 | 15.81 | ||
HSBC American Index Fund Income C | 13.67B | 11.22 | 14.49 | 15.80 | ||
HSBC American Index Fund Retail Acc | 13.67B | 7.05 | 14.75 | 15.32 | ||
HSBC American Index Fund Retail Inc | 13.67B | 7.05 | 15.24 | 15.46 | ||
HSFund Institutional Accumulation | 13.67B | 7.07 | 14.89 | 15.50 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Index Unit Trust Accumulation | 13.83B | 4.02 | 7.99 | 5.79 | ||
All Share Index Unit Trust Income | 13.83B | -0.70 | 7.89 | - | ||
VG UK Plus GBP Accumulation | 13.83B | -0.70 | 7.91 | - | ||
VG UK Institutional Plus GBP Income | 13.83B | -0.69 | 7.90 | - | ||
UK Equity Tracker Fund D Acc | 11.62B | 2.82 | 7.88 | 5.79 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Shell | GB00BP6MXD84 | 7.15 | 33.48 | -0.81% | |
AstraZeneca | GB0009895292 | 6.63 | 12,050.0 | -0.87% | |
HSBC | GB0005405286 | 5.00 | 705.50 | +0.07% | |
Unilever | GB00B10RZP78 | 4.12 | 48.80 | -0.02% | |
BP | GB0007980591 | 3.47 | 510.40 | -1.05% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review